Results 221 to 230 of about 143,360 (302)

SGLT2i use and fracture risk compared with DPP4i in patients with T2DM

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Introduction The association between sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) use and fracture risk remains inconclusive. Most previous studies have focused on treatment‐naïve patients, despite many patients in routine clinical practice initiating SGLT2i therapy after prior dipeptidyl peptidase‐4 inhibitor (DPP4i) use.
Sung‐Yen Lin, Shih‐Hao Huang, Ching‐Han Chiang, Cheng‐Jung Ho, Chung‐Hwan Chen, Li‐Nien Chien   +5 more
wiley   +1 more source

Antithrombotic Therapy after Structural Heart Disease Intervention. [PDF]

J Neuroendovasc Ther
Hara H.
europepmc   +1 more source

Early Antiplatelet Therapy in Upper Gastrointestinal Bleeding with Coronary Artery Disease: A Landmark Analysis of MIMIC-IV and eICU-CRD Databases. [PDF]

Arch Acad Emerg Med
Zhong X.
europepmc   +1 more source

Dual Antiplatelet Therapy and Very Early Neurological Deterioration after Non-Cardioembolic Stroke According to Stroke Etiology. [PDF]

Cerebrovasc Dis Extra
Pereppadan RS, Schärli S, Brülisauer S, Valletta F, Vlachos D, Schneider TR, Hellstern V, De Marchis GM, Dittrich TD.   +8 more
europepmc   +1 more source

Association of Aspirin With Improved Clinical Outcomes and Survival in Patients With Compensated Cirrhosis: A Propensity Score‐Matched Study of 25 782 Individuals

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background Pharmacologic therapies to prevent decompensation in cirrhosis remain limited. Aim To evaluate the association between aspirin use and cirrhosis‐related outcomes and mortality. Methods This retrospective cohort study utilized deidentified electronic health records from a global federated network (January 2013–July 2025). Adults with
Shahem Abbarh, Bisher Sawaf, Tiago Lemos Cerqueira, Hagen B. Huttner, Annahita Sedghi, Norma J. Diel, Timo Siepmann   +6 more
wiley   +1 more source

Role of light transmission aggregometry in predicting diffusion-weighted imaging lesions after stent-assisted coil embolization for intracranial aneurysms: a retrospective propensity score-matched study. [PDF]

Front Neurol
Kan I, Fuga M, Ishibashi T, Kato N, Hataoka S, Nagayama G, Sano T, Karagiozov KL, Murayama Y.   +8 more
europepmc   +1 more source

Hip Fracture Risk of Lemborexant and Suvorexant in Comparison With Z‐Drugs: A Target Trial Emulation

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Lemborexant and suvorexant are widely used dual orexin receptor antagonists (DORAs) for the pharmacological treatment of insomnia. Although they are generally considered safer than benzodiazepine receptor agonists (Z‐drugs) regarding adverse events including hip fractures, evidence from direct comparisons remains limited. This study
Yuichiro Matsuo, Hayato Yamana, Yusuke Sasabuchi, Hiroki Matsui, Takahide Kohro, Hideo Yasunaga   +5 more
wiley   +1 more source

The OCEANIC trial journey: from failure to breakthrough? [PDF]

Eur Heart J Cardiovasc Pharmacother
Caso V, Ten Cate H, van Gelder IC.
europepmc   +1 more source